(Q2736873)

alfuzosin (English)

3 October 2016

C₁₉H₂₇N₅O₄

1 reference

alfuzosin (English)

19 November 2016

CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC

1 reference

https://www.whocc.no/atc_ddd_index/?code=G04CA01

alfuzosin (English)

19 November 2016

7.5 milligram

route of administration

oral administration

1 reference

reference URL

1 reference

14 February 2018

World Health Organisation international non-proprietary name

alfuzosin (English)

1 reference

alfuzosin (English)

medical condition treated

3 October 2016

prostatic hypertrophy

1 reference

Drug Indications Extracted from FAERS

Food and Drug Administration

2 October 2018

prostatic hypertrophy

start time

12 June 2003

approved by

1 reference

Inxight: Drugs Database

https://drugs.ncats.io/drug/90347YTW5F

2 November 2018

reference URL

https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021287s011lbl.pdf

significant drug interaction

avanafil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-metoprolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vardenafil

1 reference

established

A reference set of clinically relevant adverse drug-drug interactions

nadolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atenolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nebivolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sildenafil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

acebutolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

betaxolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diltiazem

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tadalafil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

bisoprolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pindolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

carvedilol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

propranolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

labetalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celiprolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

levobunolol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

torsades de pointes

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clarithromycin

long QT syndrome

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

Adrenoceptor alpha 1A

subject has role

antagonist

1 reference

17 August 2016

Adrenoceptor alpha 1B

subject has role

antagonist

1 reference

17 August 2016

Adrenoceptor alpha 1D

subject has role

antagonist

1 reference

Australian pregnancy category B2

17 August 2016

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category B

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category C

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Alfuzosin

8 January 2018

1 reference

5 March 2018

adrenergic alpha-1 receptor antagonists

1 reference

InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)

Medical Subject Headings

15 March 2018

1 reference

Medical Subject Headings

15 March 2018

Alfuzosin

0 references

Identifiers

InChI

1 reference

alfuzosin (English)

19 November 2016

2 references

alfuzosin (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

81403-80-7

2 references

alfuzosin (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=81403-80-7

9 April 2021

1 reference

Alfuzosin (English)

19 November 2016

2 references

alfuzosin (English)

19 November 2016

ChEBI ID

51141

mapping relation type

2 references

ALFUZOSIN (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)

1 reference

ALFUZOSIN (English)

19 November 2016

2 references

inferred from InChIKey

splash10-0006-0119000000-90a7799e494035d224e7

1 reference

MassBank accession ID

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

splash10-0abi-5791000000-648d5529faeac9e35dc0

0 references

splash10-00di-9260000000-591f2bacf7d82aeba7e3

0 references

splash10-00di-9250000000-d107a0e9675604325bb1

0 references

splash10-00di-9340000000-f708562f3998488d7fce

0 references

splash10-00di-7910000000-3fe44ce2a42f727569e2

0 references

splash10-05fr-8900000000-dca38c682ad0b6c90b46

0 references

splash10-0bvl-9300000000-bad5c36d48e0e93a82aa

0 references

splash10-000i-0009000000-b390e2d32ee38fb79cf9

0 references

splash10-00dr-0039000000-1058f618ea52b7aa95e6

0 references

splash10-0aos-0195000000-97624e7dcce906c3a1ee

0 references

splash10-0udi-0391000000-6d58b29a79c5af262723

0 references

splash10-0udi-1970000000-b3cb9821b3584d86539f

0 references

splash10-0i6s-1920000000-50ca3c071a5548796b3a

0 references

splash10-014i-5900000000-b3a86e227650a23790ec

0 references

splash10-014i-9400000000-9929aaf0359abea0c166

0 references

splash10-014i-9100000000-b3dba930d4cfe0d28a8e

0 references

HSDB ID

7290

1 reference

Hazardous Substances Data Bank

28 October 2019

ALFUZOSIN (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.108.671

27 December 2018

ECHA Substance Infocard ID

N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide (English)

quotation

CAS no.: 81403-80-7 (English)

100.108.671

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.108.671

27 December 2018

N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide (English)

quotation

CAS no.: 81403-80-7 (English)

1 reference

Alfuzosin (English)

publication date

17 November 2015

1 reference

alfuzosin (English)

19 November 2016

alfuzosin

1 reference

Medical Subject Headings

14 March 2018

1 reference

alfuzosin (English)

19 November 2016

1 reference

Human Metabolome Database ID

HMDB0014490

2 references

based on heuristic

inferred from InChIKey

2 references

alfuzosin (English)

19 November 2016

MedlinePlus drug identifier

0 references

1 reference

alfuzosin (English)

19 November 2016

0 references

1 reference

1 reference

https://docs.openalex.org/download-snapshot/snapshot-data-format

alfuzosin (English)

3 October 2016

1 reference

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

ScienceDirect topic ID

agricultural-and-biological-sciences/alfuzosin

0 references

UMLS CUI

C0051150

1 reference